Trial Profile
A Pilot Study of SGT-53 in Conjunction With Irradiation and Chemotherapy in Children With Recurrent or Progressive CNS Malignancies
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs SGT 53 (Primary) ; Bevacizumab; Irinotecan; Temozolomide
- Indications CNS cancer
- Focus Adverse reactions
- Sponsors SynerGene Therapeutics
- 07 Feb 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 07 Feb 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 07 Feb 2022 Planned initiation date changed from 1 Dec 2021 to 1 Jun 2022.